Issue of Equity

RNS Number : 9415T

Redx Pharma plc

04 April 2016

 

4 April 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company")

Issue of Equity

The Board of Redx Pharma Plc announces the issue of 6,180,197 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") in connection with the placing announced by the Company on 24 March 2016. 

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue. Following Admission, the Company's total issued share capital will comprise 71,161,406 Ordinary Shares. This number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For more information please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Cantor Fitzgerald Europe (Nomad & Broker)	T: 020 7894 7000
Phil Davies / Michael Reynolds
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

IOEIBMJTMBJMBMF